PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE
The invention relates to pharmaceutical compositions, comprising a solid dispersion extrudate comprising any of certain active compounds that modulate cellular survival pathways implicating certain protein kinases, as described, for the treatment of cancer, and processes for the preparation of such compositions. The invention also relates to methods of administering such pharmaceutical compositions to patients for the treatment of cancer.
1 . A pharmaceutical composition comprising a solid dispersion extrudate comprising:
a polymer carrier,
a solubilizer/plasticizer,
a bioavailability enhancer, and
an active compound selected from:
3-[4-(3-Amino-1H-pyrazolo[3,4-b]pyrazin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide,
6-Cyano-3-[4-(3-methylamino-1H-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide, and
3-[4-(3-Amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide,
or a pharmaceutically acceptable salt thereof.
2 . The pharmaceutical composition of claim 1 , wherein the polymer carrier is a vinylpyrrolidinone-vinyl acetate copolymer.
3 .- 5 . (canceled)
6 . The pharmaceutical composition of claim 1 , wherein the solubilizer/plasticizer is PEG 1500.
7 .- 8 . (canceled)
9 . The pharmaceutical composition of claim 1 , wherein the bioavailability enhancer is d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS).
10 .- 11 . (canceled)
12 . The pharmaceutical composition of claim 1 , wherein the amount of the active compound in the extrudate is about 5% to about 35% w/w.
13 .- 17 . (canceled)
18 . The pharmaceutical composition of claim 1 , wherein the solid dispersion extrudate is substantially amorphous, as determined by x-ray powder diffraction analysis.
19 .- 21 . (canceled)
22 . The pharmaceutical composition of claim 1 , further comprising about 50% to about 90% w/w of one or more pharmaceutically acceptable excipients.
23 . An orally administrable preparation of an active compound comprising:
a solid dispersion extrudate comprising:
an active compound,
a polymer carrier,
a solubilizer/plasticizer, and
a bioavailability enhancer; and
one or more pharmaceutically acceptable excipients;
wherein the active compound is selected from:
3-[4-(3-Amino-1H-pyrazolo[3,4-b]pyrazin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide,
6-Cyano-3-[4-(3-methylamino-1H-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide, and
3-[4-(3-Amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carb oxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide,
or a pharmaceutically acceptable salt thereof.
24 . The pharmaceutical composition of claim 22 , wherein the pharmaceutically acceptable excipients are selected from microcrystalline cellulose, pregelatinized starch, magnesium stearate, and combinations thereof.
25 .- 28 . (canceled)
29 . A process for preparing a pharmaceutical composition,
which comprises the steps of:
(i) hot melt extruding a mixture of:
a polymer carrier,
a solubilizer/plasticizer,
a bioavailability enhancer, and
an active compound selected from:
3-[4-(3-Amino-1H-pyrazolo[3,4-b]pyrazin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide,
6-Cyano-3-[4-(3-methylamino-1H-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide, and
3-[4-(3-Amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide,
or a pharmaceutically acceptable salt thereof,
to form a solid dispersion extrudate; and
(ii) blending the resulting solid dispersion extrudate with one or more pharmaceutically acceptable excipients.
30 . The process of claim 29 , wherein the polymer carrier is a vinylpyrrolidinone-vinyl acetate copolymer.
31 . The process of claim 29 , whereinthe solubilizer is PEG 1500.
32 . The process of claim 29 , wherein the bioavailability enhancer is d-α-tocopheryl polyethylene glycol 1000 succinate.
33 . The process of claim 29 , wherein the extruding is carried out in an extruder operating with a barrel temperature comprising stages ranging from about 35° C. to about 160° C.
34 . The process of claim 29 , wherein the extruding is carried out in an extruder operating with a melt temperature ranging from about 95° C. to about 160° C.
35 . A method for the treatment of cancer in a patient in need thereof, comprising administering an effective amount of a pharmaceutical composition of claim 1 according to an intermittent dosing regimen, wherein the dosing regimen comprises administering the composition once or twice weekly and wherein the amount of the active moiety administered each week is from about 1 mg to about 500 mg.
36 . The method of claim 35 , wherein the cancer is a hematologic cancer.
37 . The method of claim 36 , wherein the hematologic cancer is a leukemia, a lymphoma, or a myeloma.
38 .- 44 . (canceled)
45 . The method of claim 35 , wherein the cancer is dependent on a PDK1-PIF-mediated substrate interaction.
46 . The method of claim 35 , wherein the method further comprises a second anti-cancer agent.